Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial
- Resource Type
- Article
- Source
- In
Cancer Pathogenesis and Therapy February 2024 - Subject
- Language
- ISSN
- 2949-7132